A
Andrew W. Bradbury
Researcher at University of Birmingham
Publications - 252
Citations - 14356
Andrew W. Bradbury is an academic researcher from University of Birmingham. The author has contributed to research in topics: Varicose veins & Abdominal aortic aneurysm. The author has an hindex of 57, co-authored 248 publications receiving 12385 citations. Previous affiliations of Andrew W. Bradbury include National Health Service & Edinburgh Royal Infirmary.
Papers
More filters
Journal ArticleDOI
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.
Donald J. Adam,Jonathan Beard,T Cleveland,Jocelyn Bell,Andrew W. Bradbury,John F. Forbes,F. G. R. Fowkes,I Gillepsie,C. V. Ruckley,Gillian M. Raab,H Storkey,Basil trial participants +11 more
TL;DR: In patients presenting with severe limb ischaemia due to infra-inguinal disease and who are suitable for surgery and angioplasty, a bypass-surgery-first and a balloon-angioplastic-first strategy are associated with broadly similar outcomes in terms of amputation-free survival, and in the short-term, surgery is more expensive than angiopLasty.
Journal ArticleDOI
Global vascular guidelines on the management of chronic limb-threatening ischemia
Michael S. Conte,Andrew W. Bradbury,Philippe Kolh,John V. White,Florian Dick,Robert Fitridge,Joseph L. Mills,Jean-Baptiste Ricco,Kalkunte R Suresh,M. Hassan Murad,Victor Aboyans,Murat Aksoy,Vlad-Adrian Alexandrescu,David G. Armstrong,Nobuyoshi Azuma,Jill J. F. Belch,Michel Bergoeing,Martin Björck,Nabil Chakfe,Stephen W.K. Cheng,Joseph Dawson,Eike Sebastian Debus,Andrew Dueck,Sue Duval,Hans-Henning Eckstein,Roberto Ferraresi,Raghvinder Gambhir,Mauro Gargiulo,Patrick J. Geraghty,Steve Goode,Bruce H. Gray,Wei Guo,Prem C. Gupta,Robert J. Hinchliffe,Prasad Jetty,Kimihiro Komori,Lawrence A. Lavery,Wei Liang,Robert A. Lookstein,Matthew T. Menard,Sanjay Misra,Tetsuro Miyata,Greg Moneta,Jose A. Munoa Prado,Alberto Munoz,Juan E. Paolini,Manesh R. Patel,Frank B. Pomposelli,Richard J. Powell,Peter A Robless,Lee C. Rogers,Andres Schanzer,Peter Schneider,Spence M. Taylor,Melina Vega de Ceniga,Martin Veller,Frank Vermassen,Jinsong Wang,Shenming Wang +58 more
TL;DR: The GVG proposes a new Global Anatomic Staging System (GLASS), which involves defining a preferred target artery path (TAP) and then estimating limb-based patency (LBP) resulting in three stages of complexity for intervention.
Journal ArticleDOI
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy
Andrew W. Bradbury,Andrew W. Bradbury,Donald J. Adam,Jocelyn Bell,John F. Forbes,F. Gerry R. Fowkes,I. Gillespie,C. V. Ruckley,Gillian M. Raab,Basil trial participants +9 more
TL;DR: Overall, there was no significant difference in AFS or OS between the two strategies, however, for those patients who survived for at least 2 years after randomization, a BSX-first revascularization strategy was associated with a significant increase in subsequent OS and a trend towards improved AFS.
Journal ArticleDOI
Treatment for diabetic foot ulcers
Peter R. Cavanagh,Peter R. Cavanagh,Benjamin A. Lipsky,Andrew W. Bradbury,Andrew W. Bradbury,Georgeanne Botek +5 more
TL;DR: People with diabetes develop foot ulcers because of neuropathy (sensory, motor, and autonomic deficits), ischaemia, or both and appropriate education for patients, the provision of posthealing footwear, and regular foot care can reduce rates of re-ulceration.
Journal ArticleDOI
Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia
Michael S. Conte,Patrick J. Geraghty,Andrew W. Bradbury,Nathanael D. Hevelone,Stuart R. Lipsitz,Gregory L. Moneta,Mark R. Nehler,Richard J. Powell,Anton N. Sidawy +8 more
TL;DR: For new catheter-based therapies in CLI, OPGs offer a feasible approach for pre-market evaluation using non-randomized trial designs and should incorporate risk stratification in design and reporting as the CLI population is heterogeneous with respect to baseline variables and expected outcomes.